Oppenheimer's decision to downgrade the stock rating reflects the uncertainty surrounding the future of the BEACON trial and the potential impact on Pliant Therapeutics' prospects. The analysts ...

Oppenheimer analysts downgraded Pliant Therapeutics stock from Outperform to Perform, following a significant development ...

Oppenheimer analyst Jeff Jones downgraded Pliant Therapeutics (PLRX) to Perform from Outperform without a price target after the company ...

Oppenheimer raised the firm’s price target on Shopify (SHOP) to $150 from $130 and keeps an Outperform rating on the shares. The company’s ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Shopify guided for a deceleration in first-quarter revenue growth to the mid-20% range, compared to the 31% increase in Q4. Oppenheimer attributed this slowdown to external factors, including foreign ...

Prothena (NASDAQ:PRTA – Free Report) had its price target boosted by Oppenheimer from $58.00 to $62.00 in a report published on Friday,Benzinga reports. They currently have an outperform rating on the ...

Get Latest and Breaking News about Bollywood and Hollywood. Todays Top News Headlines about Bollywood, News on Indian Celebrities, Photos and Videos of Movie Stars. News about Shah Rukh Khan, Salman ...